Tempest Therapeutics (TPST) Other Non-Current Liabilities (2011 - 2020)
Tempest Therapeutics (TPST) posted Other Non-Current Liabilities of $7000.0 for Q1 2020, down 56.25% sequentially from $16000.0 in Q4 2019, and down 96.35% YoY from $192000.0 in Q2 2019.
Tempest Therapeutics (TPST) Other Non-Current Liabilities (2011 - 2020) Analysis & Trends
Tempest Therapeutics has reported Other Non-Current Liabilities for 10 years, with the latest figure at $7000.0 in Q1 2020.
- Quarterly Other Non-Current Liabilities fell 96.35% year-over-year to $7000.0 in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $7000.0 (down 96.35% YoY) and the FY2019 annual result came in at $16000.0, down 97.87% from the prior year.
- Other Non-Current Liabilities fell to $7000.0 in Q1 2020 per TPST's latest filing, from $16000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $1.1 million in Q4 2016 and troughed at $7000.0 in Q1 2020.
- A 5-year average of $552642.9 and a median of $620000.0 in 2018 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2016 and 2019: Other Non-Current Liabilities jumped 114.62% in 2016, then plunged 97.87% in 2019.
- Over 5 years, Other Non-Current Liabilities stood at $1.1 million in 2016, then slumped by 32.71% to $751000.0 in 2017, then rose by 0.13% to $752000.0 in 2018, then slumped by 97.87% to $16000.0 in 2019, then tumbled by 56.25% to $7000.0 in 2020.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $7000.0, $16000.0, and $229000.0 for Q1 2020, Q4 2019, and Q3 2019 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Tempest Therapeutics | 4.23 Mn | 3.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 7,000.00 |
| Dec 31, 2019 | 16,000.00 |
| Sep 30, 2019 | 229,000.00 |
| Jun 30, 2019 | 227,000.00 |
| Mar 31, 2019 | 192,000.00 |
| Dec 31, 2018 | 752,000.00 |
| Sep 30, 2018 | 442,000.00 |
| Jun 30, 2018 | 576,000.00 |
| Mar 31, 2018 | 664,000.00 |
| Dec 31, 2017 | 751,000.00 |
| Sep 30, 2017 | 834,000.00 |
| Jun 30, 2017 | 925,000.00 |
| Mar 31, 2017 | 1.01 Mn |
| Dec 31, 2016 | 1.12 Mn |
| Dec 31, 2015 | 520,000.00 |
| Sep 30, 2015 | 358,000.00 |
| Jun 30, 2015 | 149,000.00 |
| Mar 31, 2015 | 74,000.00 |
| Dec 31, 2014 | 73,000.00 |
| Sep 30, 2014 | 71,000.00 |